1 year ago
Bluebird CAR-T Multiple Myeloma
Bluebird CAR-T Multiple Myeloma Abecma is the world’s first approved BCMA-targeted CAR-T cell therapy, co-developed by Bristol Myers Squibb (BMS) and Bluebird Bio. It is a first-in-class, BCM...
1 year ago
1 year ago
BB2121 CAR-T(Abecma、Idecabtagene Vicleucel、ide-cel)
BB2121 CAR-T(Abecma、Idecabtagene Vicleucel、ide-cel) BB2121 CAR-T, now known as Abecma, Idecabtagene Vicleucel, or ide-cel. Bluebird bio initially designed and compared four second-generation anti...
1 year ago
CAR-T Abecma Multiple Myeloma Treatment Increases PFS by More Than Three Times, and CAR-T Cell Therapy Targeting BCMA has been re Approved by the FDA
CAR-T Abecma Multiple Myeloma Treatment Increases PFS by More Than Three Times, and CAR-T Cell Therapy Targeting BCMA has been re Approved by the FDA Bristol Myers Squibb and 2seventy bio recently ...
1 year ago
China’s First CAR-T Trial: “Pay-for-Performance” Introduced!
China’s First CAR-T Trial: “Pay-for-Performance” Introduced! CAR-T China has taken a groundbreaking step towards pay-for-performance! Fosun Kite announces an exciting initi...
1 year ago
Abecma (Ideabtagene Vicleucel) FDA Approval Date and Brief Introduction of Drugs
Abecma (Ideabtagene Vicleucel) FDA Approval Date and Brief Introduction of Drugs Overview of FDA Approval of Abecma On March 26, 2021, Abecma® (Idecabtagene Vicleucel, ide-cel) received approval fr...
1 year ago
On August 19, 2021, Abecma(Idecabtagene Vicleucel) Granted EMA Approval in the EU for the Treatment of Relapsed and Refractory Multiple Myeloma
On August 19, 2021, Abecma(Idecabtagene Vicleucel) Granted EMA Approval in the EU for the Treatment of Relapsed and Refractory Multiple Myeloma Abecma Approved for Marketing in Europe On August 19,...
1 year ago
On April 4, 2024,Abecma® (Idecabtagene Vicleucel) FDA Approval for the Treatment of Relapsed or Refractory Multiple Myeloma
On April 4, 2024,Abecma® (Idecabtagene Vicleucel) FDA Approval for the Treatment of Relapsed or Refractory Multiple Myeloma On April 4th, 2024, Abecma® (idecabtagene vicleucel) received approval fr...
1 year ago
Can Myeloma CAR-T Cell Therapy Achieve Cure?
Can Myeloma CAR-T Cell Therapy Achieve Cure? Multiple Myeloma (MM) is a monoclonal plasma cell malignant proliferative tumor, accounting for approximately 10% of hematological malignancies. Cytogen...
1 year ago
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China Pan-Cancer ICP-723 On April 11, 2022, InnoCare Pharma unveiled the preclinical data ...
1 year ago
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company
The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company Mutiple myeloma #Legend Biotech How to advance #CARTc...
1 year ago
Carvykti Target is BCMA, Brief Introduction of BCMA Target
Carvykti Target is BCMA, Brief Introduction of BCMA Target Carvykti Target is BCMA BCMA (B-Cell Maturation Antigen) is a specific target for multiple myeloma, and therapies targeting BCMA are consi...
1 year ago
GPRC5D Targeted CAR-T Cells for Myeloma
GPRC5D Targeted CAR-T Cells for Myeloma In addition to serving as an antibody target, GPRC5D is a promising CAR target. Introduction to a CART targeting GPRC5D. Main Content Early clinical results...